Evidence map›Paper›PMID 40891611›Full record

Trial reportCancer medicine2025

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.

Ida Russo, Valentina Di Ruscio, Maria Antonietta De Ioris, Giada Del Baldo, Maria Debora De Pasquale, Paola Valente, Enrico Opocher, Raffaele Parrozzani, Angela Di Giannatale, Maria Giuseppina Cefalo and 14 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ida RussoOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-7030-8639
Valentina Di RuscioOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Antonietta De IorisOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giada Del BaldoOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Debora De PasqualeOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola ValenteOphthalmology Unit, Bambino Gesù IRCCS Children's Hospital, Passoscuro, Rome, Italy.
Enrico OpocherHematology Oncology Division, Department of Women's and Children's Health, University of Padua, Padua, Italy.
Raffaele ParrozzaniDepartment of Ophthalmology, University of Padua, Padua, Italy.
Angela Di GiannataleOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Maria Giuseppina CefaloOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Annalisa SerraOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giuseppe Maria MilanoOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Daniela LongoNeuroradiology Unit, "Bambino Gesù" Children's Hospital IRCCS, Rome, Italy.
Alessia CarboniNeuroradiology Unit, "Bambino Gesù" Children's Hospital IRCCS, Rome, Italy.
Rita De VitoPathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
Gianluigi NataliInterventional Radiology Unit, Department of Surgery, Bambino Gesù Children's Hospital, Rome, Italy.
Gemma D'EliaLaboratory of Medical Genetics, Molecular Genetics Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Gianni BisognoHematology Oncology Division, Department of Women's and Children's Health, University of Padua, Padua, Italy.
Angela MastronuzziOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Raffaele CozzaOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Rita AlaggioPathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
Antonino RomanzoOphthalmology Unit, Bambino Gesù IRCCS Children's Hospital, Passoscuro, Rome, Italy.
Luca BuzzonettiOphthalmology Unit, Bambino Gesù IRCCS Children's Hospital, Passoscuro, Rome, Italy.
Franco LocatelliOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study presents the outcomes of high-risk group retinoblastoma (Rb) patients enrolled in the AIEOP RTB 012 Protocol.

methodsPatients with intraocular unilateral Rb classified as group C/D according to "International Intraocular Retinoblastoma Classification" (IIRC), as well as those with bilateral Rb with at least one eye group C/D/E-IIRC, were treated with four cycles of carboplatin/etoposide combined with focal treatments. The primary endpoint was to evaluate ocular event-free survival (EFS) and overall survival (OS), where events were defined as the need for radiotherapy, eye enucleation, and second-line treatment. Visual acuity (VA) was assessed in all available cases.

resultsBetween February 2012 and September 2017, 60 patients were enrolled (88 eyes), 32 unilateral Rb, 28 bilateral. Twelve eyes were classified as group A/B, 15 group C, 40 group D, and 21 group E. At a median follow-up of 8.71 years, 42/88 eyes were preserved. The 2- and 5-year eye EFS rates were 31.1% (95% CI: 24.4-44.0) and 29.5% (95% CI: 20.4-39.2), respectively. The corresponding 2- and 5-year eye OS rates were 63.3% (95% CI: 52.7-72.7) and 48.9% (95% CI: 38.1-58.8). Ocular survival significantly differed across IIRC groups, with 2- and 5-year survival rates of 100% for group A/B, 86.7% and 73.3% for group C, 65% and 42.5% for group D, and 23.8% and 14.3% for group E, respectively (p < 0.05). No severe toxicity was reported. Among 28 bilateral Rb patients, 12 had VA of at least 20/30 according to the Snellen chart.

conclusionThe AIEOP RTB 012 protocol has proven to be both safe and effective, ensuring a favorable final VA.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsRetinal NeoplasmsRetinoblastomaCarboplatinChildChild, PreschoolEtoposideEye EnucleationFemaleHumansInfantMaleProspective StudiesTreatment OutcomeVisual AcuityCarboplatinEtoposidehigh‐risk diseaseintraocularocular survivalretinoblastomavisual outcome

Identifiers

PMID40891611
PMCPMC12403015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.